CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Perseus Proteomics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Perseus Proteomics Inc
Park Bldg., 4-7-6, Komaba
Phone: +81 362648268p:+81 362648268 CHUO-KU, TKY  103-0015  Japan Ticker: 48824882

Business Summary
Perseus Proteomics Inc is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The Company is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20233/31/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Executive Officer, Representative Director TakuyaYokokawa 59 1/1/2019 3/1/2018
Executive Officer, Director of Administration, Director ShinichiSuzukawa 67 6/1/2020 6/1/2020
Executive Officer, Director of Research and Development, Director of Business Development, Director ShinjiHagiwara 58 6/1/2023 6/1/2023
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 24 (As of 3/31/2023)
Outstanding Shares: 11,829,953 (As of 12/31/2023)
Shareholders: 5,171
Stock Exchange: TYO
Fax Number: +81 336687776


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024